Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Sarepta Therapeutics (SRPT) Received its Third Buy in a Row
08:13am, Thursday, 23'rd Apr 2020
After Cowen & Co. and RBC Capital gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received
Mizuho Securities Thinks Xeris Pharmaceuticals' Stock is Going to Recover
08:11am, Thursday, 23'rd Apr 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The
Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover
08:11am, Thursday, 23'rd Apr 2020
In a report released today,
Difei Yang
from Mizuho Securities maintained a
Buy
rating on Xeris Pharmaceuticals (
XERS
–
Research Report
), with a price target of
$14.00
. The company’s shares clos
Global Polymer-Drug Conjugate Market (2020 to 2025) - Analysis and Forecast - ResearchAndMarkets.com
05:12pm, Wednesday, 22'nd Apr 2020
The "Polymer-Drug Conjugate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application" report has been added to ResearchAndMarke
Benchmark Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target to $26
12:13pm, Wednesday, 22'nd Apr 2020Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma NKTR
11:46am, Wednesday, 22'nd Apr 2020
Benchmark starts Nektar at Buy, has conviction in bempeg's odds in melanoma Benchmark NKTR
BofA likes Johnson & Johnson in premarket analyst action
11:38am, Wednesday, 22'nd Apr 2020
Adaptimmune (NASDAQ:ADAP) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities.Autolus Therapeutics (NASDAQ:AUTL) initiated with Buy rating and $18 (90% upside) p
Nektar initiated with a Buy at Benchmark NKTR
11:15am, Wednesday, 22'nd Apr 2020
Nektar initiated with a Buy at Benchmark Benchmark NKTR
Exane Derivatives Sells 11,246 Shares of Nektar Therapeutics (NASDAQ:NKTR)
10:20am, Tuesday, 21'st Apr 2020
Exane Derivatives lessened its stake in Nektar Therapeutics (NASDAQ:NKTR) by 79.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund o
Nektar Therapeutics (NASDAQ:NKTR) Director Sells $147,040.00 in Stock
09:16am, Monday, 20'th Apr 2020
Nektar Therapeutics (NASDAQ:NKTR) Director Robert Chess sold 8,000 shares of the stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $18.38, for a total value of
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.44%
12:00am, Monday, 20'th Apr 2020
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.44%
2 Biotechs Battling Against Kidney Cancer
12:10pm, Saturday, 18'th Apr 2020
New combination trials bring hope for patients and investors.
Mizuho Securities Thinks Xeris Pharmaceuticals' Stock is Going to Recover
12:35pm, Friday, 17'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $18.00. The company's shares
Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover
12:35pm, Friday, 17'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a
